X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 18f-av-45
2. 2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-5-(4-methylaminostyryl)pyridine
3. 4-(2-(6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-n-methylbenzamide
4. Amyvid
5. Florbetapir
6. Florbetapir F 18
7. Florbetapir F18
1. Florbetapir F-18
2. Amyvid
3. Florbetapir F 18
4. Florbetapir
5. 956103-76-7
6. 18f-av-45
7. 18f-av45
8. Florbetapir(18-f)
9. Florbetapir, F-18
10. Chebi:66880
11. (18f)av-45
12. Av-45 F-18
13. Florbetapir (18f) [inn]
14. 6w15z5r0ru
15. Av45 F-18
16. Florbetapir F-18 (usan)
17. Benzenamine, 4-((1e)-2-(6-(2-(2-(2-(fluoro-18f)ethoxy)ethoxy)ethoxy)-3- Pyridinyl)ethenyl)-n- Methyl-
18. Florbetapir F-18 [usan]
19. 4-{(e)-2-[6-(2-{2-[2-((18)f)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-n-methylaniline
20. Benzenamine, 4-[(1e)-2-[6-[2-[2-[2-(fluoro-18f)ethoxy]ethoxy]ethoxy]-3-pyridinyl]ethenyl]-n-methyl-
21. Av-45 Compound
22. Amyvid (tn)
23. Pet Av-45
24. Unii-6w15z5r0ru
25. Av-45
26. Florbetapir F18
27. 18fav45
28. Florbetapir F-18 [usan:inn]
29. 4-((1e)-2-(6-(2-(2-(2-(18f)fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)ethenyl)-n- Methylbenzenamine
30. 4-((1e)-2-(6-{2-(2-(2-(18f)fluoroethoxy)ethoxy)ethoxy}pyridin-3-yl)ethenyl)-n- Methylbenzenamine
31. 4-[(e)-2-[6-(2-{2-[2-(18f)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl]-n-methylaniline
32. 4-{(e)-2-[6-(2-{2-[2-(18f)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-n-methylaniline
33. [18f]florbetapir
34. Florbetapir-fluorine-18
35. Gtpl7344
36. Chembl1774461
37. Schembl14826096
38. Florbetapir F 18 [mi]
39. Dtxsid80241898
40. Bdbm50484946
41. Florbetapir (18f) [who-dd]
42. Db09149
43. Florbetapir (18f) [ema Epar]
44. Florbetapir F-18 [orange Book]
45. D09617
46. Q5460495
47. 4-(2-(6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-n-methylbenzamide
48. 4-[(e)-2-[6-[2-[2-(2-(18f)fluoranylethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-n-methylaniline
| Molecular Weight | 359.4 g/mol |
|---|---|
| Molecular Formula | C20H25FN2O3 |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 12 |
| Exact Mass | 359.187455 g/mol |
| Monoisotopic Mass | 359.187455 g/mol |
| Topological Polar Surface Area | 52.6 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 376 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Amyvid |
| PubMed Health | Florbetapir F-18 (Injection) |
| Drug Classes | Diagnostic Agent, Radiopharmaceutical Imaging |
| Drug Label | Amyvid contains florbetapir F 18, a molecular imaging agent that binds to -amyloid aggregates, and is intended for use with PET imaging of the brain. Chemically, florbetapir F 18 is described as (E)-4-(2-(6-(2-(2-(2[18F] fluoroethoxy)ethoxy)ethoxy)... |
| Active Ingredient | Florbetapir f-18 |
| Dosage Form | Solution |
| Route | Intravenous |
| Strength | 10ml (13.5-51mci/ml); 10-50ml (13.5-51mci/ml); 10-30ml (13.5-51mci/ml) |
| Market Status | Prescription |
| Company | Avid Radiopharms |
| 2 of 2 | |
|---|---|
| Drug Name | Amyvid |
| PubMed Health | Florbetapir F-18 (Injection) |
| Drug Classes | Diagnostic Agent, Radiopharmaceutical Imaging |
| Drug Label | Amyvid contains florbetapir F 18, a molecular imaging agent that binds to -amyloid aggregates, and is intended for use with PET imaging of the brain. Chemically, florbetapir F 18 is described as (E)-4-(2-(6-(2-(2-(2[18F] fluoroethoxy)ethoxy)ethoxy)... |
| Active Ingredient | Florbetapir f-18 |
| Dosage Form | Solution |
| Route | Intravenous |
| Strength | 10ml (13.5-51mci/ml); 10-50ml (13.5-51mci/ml); 10-30ml (13.5-51mci/ml) |
| Market Status | Prescription |
| Company | Avid Radiopharms |
Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
FDA Label
This medicinal product is for diagnostic use only.
Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of -amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimers disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.
A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.
Following intravenous injection, florbetapir F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain. Subsequently, cerebral perfusion decreases the brain florbetapir F 18 content, with differential retention of the drug in areas that contain -amyloid aggregates compared to areas that lack the aggregates.
V09AX05
V - Various
V09 - Diagnostic radiopharmaceuticals
V09A - Central nervous system
V09AX - Other central nervous system diagnostic radiopharmaceuticals
V09AX05 - Florbetapir (18F)
Absorption
The time-activity curves for florbetapir F 18 in the brain of subjects with positive scans show continual signal increases from time zero through 30 minutes post-administration, with stable values thereafter up to at least 90 minutes post-injection. Following the intravenous administration of 370 MBq (10 mCi) of florbetapir F 18 to healthy volunteers, the drug was distributed throughout the body with less than 5% of the injected F 18 radioactivity present in the blood by 20 minutes following administration, and less than 2% present by 45 minutes after administration.
Route of Elimination
Whole body scanning following the intravenous injection showed accumulation of radioactivity in the liver within four minutes post-injection, followed by elimination of the radioactivity predominantly through the biliary/gastrointestinal tract with much lower radioactivity detected in the bladder. Essentially all radioactivity collected in the urine was present as polar metabolites of florbetapir F 18.
The residual F 18 in circulation during the 30-90 minute imaging window was principally in the form of polar F 18 metabolites. Essentially all radioactivity collected in the urine was present as polar metabolites of florbetapir F 18. Three metabolites have been discovered and identified as [18F]AV-160 (desmethyl-[18F]AV-45), [18F]AV-267 (N-acetyl[18F]AV-160), and an [18F]-Polar species, the identity of which has not been confirmed. Additionally, although metabolites may make some contribution to signal detection, particularly to the nontarget activity, it is concluded that there will be minimal interference from these radiolabeled metabolites to the amyloid target binding in the [18F]AV-45 brain PET image (Wong et al, 2010).
Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.
Market Place
